The Synthesis and Bioassay of Novel Pyrroles

Information

  • Research Project
  • 8271103
  • ApplicationId
    8271103
  • Core Project Number
    R15CA067236
  • Full Project Number
    2R15CA067236-05A1
  • Serial Number
    067236
  • FOA Number
    PA-10-070
  • Sub Project Id
  • Project Start Date
    7/1/1996 - 28 years ago
  • Project End Date
    6/30/2016 - 8 years ago
  • Program Officer Name
    FU, YALI
  • Budget Start Date
    7/11/2012 - 12 years ago
  • Budget End Date
    6/30/2016 - 8 years ago
  • Fiscal Year
    2012
  • Support Year
    05
  • Suffix
    A1
  • Award Notice Date
    7/11/2012 - 12 years ago
Organizations

The Synthesis and Bioassay of Novel Pyrroles

DESCRIPTION (provided by applicant): This proposal represents a continuation of work initiated under NIH AREA grant CA 67236-04. Natural products of marine origin continue to be a rich source of biologically interesting compounds and pyrrole containing marine natural products in particular have demonstrated activity as anti-tumor agents, multidrug resistant reversal agents, vascular disrupting agents and inhibitors of HIV integrase. These pyrrole containing natural products are usually characterized by highly oxygenated phenyl or heterocyclic groups attached at carbons 3 and 4 of the pyrrole ring system along with carbonyl containing functionality located at carbons 2 and/or 5. The synthetic methodology that we have established and are developing allows for rapid construction of highly substituted and highly functionalized pyrroles. This methodology also allows for great structural diversity for structure activity relationship (SAR) studies, which could lead to chemotherapeutic agents with increased potency and decreased toxic side effects. Work proposed for the new funding cycle will involve applying our synthetic methodology along with some new and complimentary methodology to the synthesis of the marine natural products lycogallic acid, lycogarubin B, lycogarubin C, lynamycin E and related compounds, such as new analogs of JG-03-14. JG-03-14 is an interesting synthetic pyrrole, which has emerged from our research efforts, and has demonstrated in vitro activity (IC50 of 35 nM) against breast cancer cell lines and in vivo activit against a mouse prostate cancer xenograft. JG-03-14 has also been shown to be active against drug resistant breast cancer cell lines, an inhibitor of tubulin polymerization, a vascular disrupting agent and a promoter of autophagic cell death. Our current and evolving synthetic methodologies will allow us to extend our targets to these important bioactive, natural products and new JG-03-14 analogs. All of the target molecules, their precursors and their analogs will be subject to biological evaluation by a team of highly experienced collaborators and such studies will be coupled with molecular modeling by an additional collaborator. Since our project encompasses synthesis, bioassay and molecular modeling driven SAR, we believe that a novel and viable clinical candidate for cancer chemotherapy may well emerge from such studies. PUBLIC HEALTH RELEVANCE: The development of new and novel chemotherapeutic agents for a particular disease state continues to depend to a significant degree on the discovery of a lead compound, which can be further developed into a viable drug candidate. Naturally occurring compounds continue to be a major source of drug leads and our current proposal seeks to utilize our pyrrole forming reactions to synthesize biologically interesting natural products such as lycogallic acid, lycogarubins B and C, lynamycin E and related compounds. In addition to these natural product targets, we will continue to develop new derivatives of our synthetic pyrrole, JG-03-14, which continues to exhibit promising biological properties. The majority of these natural products, their analogs and precursors along with JG-03-14 analogs will be biologically evaluated and computationally modeled by a team of highly experienced collaborators.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R15
  • Administering IC
    CA
  • Application Type
    2
  • Direct Cost Amount
    250000
  • Indirect Cost Amount
    98572
  • Total Cost
    348572
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NCI:348572\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    SBCB
  • Study Section Name
    Synthetic and Biological Chemistry B Study Section
  • Organization Name
    UNIVERSITY OF RICHMOND
  • Organization Department
    CHEMISTRY
  • Organization DUNS
    056915069
  • Organization City
    RICHMOND
  • Organization State
    VA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    231730001
  • Organization District
    UNITED STATES